Artiva Biotherapeutics (ARTV) to Release Earnings on Thursday

Artiva Biotherapeutics (NASDAQ:ARTV) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.88) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03. On average, analysts expect Artiva Biotherapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Trading Up 16.9%

Shares of ARTV stock opened at $12.39 on Thursday. The company has a market cap of $306.28 million, a price-to-earnings ratio of -3.62 and a beta of 2.86. The stock has a 50 day simple moving average of $7.44 and a 200-day simple moving average of $5.30. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $14.53.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the period. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter worth $41,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Artiva Biotherapeutics in the 4th quarter valued at about $91,000. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $53,000. Finally, Renaissance Technologies LLC raised its stake in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after purchasing an additional 37,053 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.